Lexicon Pharmaceuticals Newswire

Lexicon Pharmaceuticals Newswire

Comprehensive Real-Time News Feed for Lexicon Pharmaceuticals.

Results 1 - 20 of 314 in Lexicon Pharmaceuticals

  1. Lexicon Pharmaceuticals Inc. (LXRX) Stock Price Down 6%Read the original story w/Photo

    Wednesday Aug 24 | Daily Political

    Lexicon Pharmaceuticals Inc. 's share price was down 6% during trading on Wednesday . The company traded as low as $14.41 and last traded at $14.52, with a volume of 849,115 shares trading hands.

    Comment?

  2. Lexicon Pharmaceuticals (LXRX) - Investment Analysts' Recent Ratings UpdatesRead the original story w/Photo

    Tuesday Aug 23 | AmericanBankingNews.com

    8/11/2016 - Lexicon Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. According to Zacks, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery ...

    Comment?

  3. Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Given Consensus Rating of "Hold" by AnalystsRead the original story w/Photo

    Monday Aug 22 | Daily Political

    Shares of Lexicon Pharmaceuticals Inc. have been assigned an average recommendation of "Hold" from the nine research firms that are presently covering the firm. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company.

    Comment?

  4. Lexicon Pharmaceuticals Inc. (LXRX) Shares Down 3.6%Read the original story w/Photo

    Wednesday Aug 17 | Daily Political

    Lexicon Pharmaceuticals Inc. shares dropped 3.6% during mid-day trading on Tuesday . The company traded as low as $15.64 and last traded at $15.65, with a volume of 1,229,639 shares traded.

    Comment?

  5. Lexicon Pharmaceuticals Inc. (LXRX) Downgraded by Zacks Investment ResearchRead the original story w/Photo

    Tuesday Aug 16 | Daily Political

    ... " LXRX has been the subject of a number of other reports. Wedbush upped their price target on Lexicon Pharmaceuticals from $28.00 to $30.00 and gave the company an outperform rating in a research report on Tuesday, May 31st. Citigroup Inc. assumed ...

    Comment?

  6. Lexicon Pharmaceuticals Inc. (LXRX) Rating Reiterated by Needham & Company LLCRead the original story w/Photo

    Monday Aug 15 | Daily Political

    ... modified their holdings of LXRX. Bridger Management LLC purchased a new position in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $12,308,000. Eagle Asset Management Inc. boosted its position in shares of Lexicon ...

    Comment?

  7. Lexicon Pharmaceuticals Inc. (LXRX) Stock Rating Lowered by Zacks Investment ResearchRead the original story w/Photo

    Sunday Aug 14 | AmericanBankingNews.com

    ... also recently issued reports on the company. Stifel Nicolaus increased their price objective on Lexicon Pharmaceuticals from $25.00 to $26.00 and gave the stock a "buy" rating in a report on Friday, August 5th. Wedbush increased their price ...

    Comment?

  8. Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at Needham & Company LLCRead the original story w/Photo

    Saturday Aug 13 | AmericanBankingNews.com

    ... recently bought and sold shares of the company. Bridger Management LLC bought a new stake in Lexicon Pharmaceuticals during the first quarter worth approximately $12,308,000. Eagle Asset Management Inc. boosted its position in shares of Lexicon ...

    Comment?

  9. Lexicon Pharma To Present At The 2016 Healthcare ConferenceRead the original story

    Thursday Aug 11 | BioSpace

    /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that Lexicon management will present at the 2016 Wedbush PacGrow Healthcare Conference on A webcast of the presentation will be available through Lexicon's website at ...

    Comment?

  10. Lexicon to Present at the 2016 Wedbush Pacgrow Healthcare ConferenceRead the original story

    Friday Aug 12 | PressReleasePoint

    Lexicon Pharmaceuticals, Inc. announced today that Lexicon management will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 8:35 a.m. Eastern Time in New York. Lexicon management will provide an overview of Lexicon's clinical development programs and milestones.

    Comment?

  11. Lexicon Pharmaceuticals (LXRX) - Analysts' Weekly Ratings ChangesRead the original story w/Photo

    Thursday Aug 11 | AmericanBankingNews.com

    Several brokerages have updated their recommendations and price targets on shares of Lexicon Pharmaceuticals in the last few weeks: 8/11/2016 - Lexicon Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. According to Zacks, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology.

    Comment?

  12. Zacks Investment Research Lowers Lexicon Pharmaceuticals Inc. (LXRX) to SellRead the original story w/Photo

    Wednesday Aug 10 | AmericanBankingNews.com

    ... have made changes to their positions in LXRX. BlackRock Fund Advisors raised its stake in shares of Lexicon Pharmaceuticals by 5.9% in the first quarter. BlackRock Fund Advisors now owns 2,322,113 shares of the biopharmaceutical company's stock ...

    Comment?

  13. Lexicon Pharmaceuticals Inc. to Post FY2016 Earnings ofRead the original story w/Photo

    Wednesday Aug 10 | AmericanBankingNews.com

    Lexicon Pharmaceuticals Inc. - Investment analysts at Gabelli issued their FY2016 earnings estimates for Lexicon Pharmaceuticals in a report issued on Monday. Gabelli analyst K. Kedra expects that the firm will earn per share for the year.

    Comment?

  14. Wedbush Increases Lexicon Pharmaceuticals Inc. (LXRX) Price Target to $31.00Read the original story w/Photo

    Tuesday Aug 9 | Daily Political

    ... link . Several other analysts also recently issued reports on LXRX. Citigroup Inc. began coverage on Lexicon Pharmaceuticals in a research note on Tuesday, August 2nd. They issued a "buy" rating and a $21.00 price target for the company. Needham & ...

    Comment?

  15. Lexicon Pharmaceuticals Inc. (LXRX) PT Raised to $26.00Read the original story w/Photo

    Tuesday Aug 9 | Daily Political

    ... price objective suggests a potential upside of 60.30% from the stock's current price. Shares of Lexicon Pharmaceuticals ( NASDAQ:LXRX ) traded up 1.44% during trading on Friday, hitting $16.22. 482,706 shares of the stock traded hands. The firm's ...

    Comment?

  16. Lexicon Pharmaceuticals Inc. (LXRX) Lifted to Hold at Zacks Investment ResearchRead the original story w/Photo

    Monday Aug 8 | Daily Political

    ... " Other analysts also recently issued reports about the company. Citigroup Inc. assumed coverage on Lexicon Pharmaceuticals in a research report on Tuesday, August 2nd. They set a buy rating and a $21.00 target price for the company. Cowen and ...

    Comment?

  17. Wedbush Increases Lexicon Pharmaceuticals Inc. (LXRX) Price Target to $31.00Read the original story w/Photo

    Sunday Aug 7 | AmericanBankingNews.com

    ... issued reports about the stock. Cowen and Company reaffirmed a "market perform" rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, May 3rd. JPMorgan Chase & Co. reaffirmed a "hold" rating and issued a $16.00 target price on shares ...

    Comment?

  18. Lexicon Pharmaceuticals' (LXRX) CEO Lonnel Coats on Q2 2016 Results - Earnings Call TranscriptRead the original story w/Photo

    Thursday Aug 4 | Seeking Alpha

    Good morning. Thank you for standing by, and welcome to the Lexicon Pharmaceuticals Second Quarter 2016 Financial Results Conference Call.

    Comment?

  19. Lexicon Pharmaceuticals Inc. (LXRX) Given New $26.00 Price Target at Stifel NicolausRead the original story w/Photo

    Saturday Aug 6 | AmericanBankingNews.com

    ... recently weighed in on LXRX. Cowen and Company reiterated a "market perform" rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, May 3rd. Needham & Company LLC reissued a "buy" rating and set a $21.00 target price on shares ...

    Comment?

  20. Lexicon Pharmaceuticals Inc. (LXRX) Price Target Increased to $26.00 by Analysts at Stifel NicolausRead the original story w/Photo

    Friday Aug 5 | AmericanBankingNews.com

    ... equities research analysts have also commented on the company. Citigroup Inc. started coverage on Lexicon Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $21.00 price target on the stock. Zacks Investment Research raised ...

    Comment?